| Literature DB >> 35805900 |
Jiawei Mo1,2,3, Zhijun Wang1,2,3, Qingchun Liu1,2,3, Zhenhui Li1,2,3, Qinghua Nie1,2,3.
Abstract
Disuse muscle atrophy is identified as the physiological, biochemical, morphological, and functional changes during restricted movement, immobilization, or weightlessness. Although its internal mechanism has been extensively studied in mammals and was thought to be mainly related to oxidative stress, it was unclear whether it behaved consistently in non-mammals such as chickens. In this study, we tried to construct a disuse atrophy model of the gastrocnemius muscle in chickens by limb immobilization, and collected the gastrocnemius muscles of the fixed group and the control group for RNA sequencing. Through analysis of muscle loss, HE staining, immunohistochemistry, and oxidative stress level, we found that limb immobilization could lead to loss of muscle mass, decrease in muscle fiber diameter, decrease in the proportion of slow muscle fibers, and increase in the proportion of fast muscle fibers, and also cause elevated levels of oxidative stress. In addition, a total of 565 different expression genes (DEGs) were obtained by RNA sequencing, which was significantly enriched in the biological processes such as cell proliferation and apoptosis, reactive oxygen species metabolism, and fast and slow muscle fiber transformation, and it showed that the FOXO signaling pathway, closely related to muscle atrophy, was activated. In brief, we initially confirmed that limb immobilization could induce disuse atrophy of skeletal muscle, and oxidative stress was involved in the process of disuse muscle atrophy.Entities:
Keywords: RNA-seq; ROS; chicken; disuse muscle atrophy; oxidative stress
Mesh:
Year: 2022 PMID: 35805900 PMCID: PMC9266690 DOI: 10.3390/ijms23136892
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Construction plan of disuse muscle atrophy model.
| Control Group (C Group) | Treatment Group (S Group) | ||
|---|---|---|---|
| Left lower limb | Right lower limb | Left lower limb | Right lower limb |
| (C-L group) | (C-R group) | (S-L group) | (S-R group) |
| No treatment | No treatment | Immobilization | No treatment |
Figure 1Atrophy model leads to loss of muscle mass. (A) Live body weight of each group before sampling. (B) Schematic diagram of the gastrocnemius muscle of each group after sampling. (C) Fresh weight of gastrocnemius muscle of each group. (D) Mean difference rate of gastrocnemius fresh weight within the group. Data are presented as mean ± SEM (n = 6 biologically independent samples). * p < 0.05; ** p < 0.01 (Student’s t-test).
Figure 2Atrophy model results in reduction of muscle fiber diameter and altered muscle fiber composition type. (A) Hematoxylin and eosin (H&E) staining of gastrocnemius muscle (scale bar = 50 μm). (B) Distribution of muscle fiber diameter size. (C) Statistics of average muscle fiber diameter size. (D) Distribution of cross-sectional area of muscle fiber. (E) Statistics of average cross-sectional area of muscle fiber. (F) Immunohistochemical staining for composition type of gastrocnemius muscle fiber. (G) Statistics of MYH1A/MYH7B protein content for composition type of gastrocnemius muscle fiber. Data are presented as mean ± SEM (n = 3 biologically independent samples). * p < 0.05; *** p < 0.001 (Student’s t-test).
Figure 3Increased levels of oxidative stress in atrophy model. (A) Relative catalase activity analysis. (B) Relative MDA content analysis. (C) Relative total antioxidant capacity analysis. Data are presented as mean ± SEM (n = 3 biologically independent samples). * p < 0.05; ** p < 0.01; *** p < 0.001 (Student’s t-test).
Figure 4DEGs among 3 groups of gastrocnemius tissues. (A–C) Scatter plots of mRNA expression distribution between S−L group and C group, or between S−L group and S−R group, or between S−L group and C group. Color: Blue indicates downregulated genes, red indicates upregulated genes, and gray indicates nondifferentially expressed genes. (D) Quantity statistics of DEGs, in which the red column represents upregulated DEGs and the green represents downregulated DEGs. (E) Principal component analysis of differentially expressed genes among 3 groups. (F) Heatmap of differentially expressed genes (DEGs) among 3 groups, in which rows represent genes, and columns represent different groups.
Figure 5GO and KEGG pathway analysis for DEGs. (A) Top 20 terms of the biological process part of GO enrichment analysis for DEGs. (B) Top 20 terms of cell component part of GO enrichment analysis for DEGs. (C) Top 20 terms of molecular functions of GO enrichment analysis for DEG. (D) Top 20 enriched pathways in KEGG pathway analysis for DEGs. (E) Validation of transcriptome sequencing results by qPCR. Data are presented as mean ± SEM (n = 6 biologically independent samples). * p < 0.05; *** p < 0.001 (Student’s t-test).
Top 20 enriched KEGG pathways (p < 0.05).
| Pathways | −log ( | Rich Ratio | Focus Molecules |
|---|---|---|---|
| TGF-beta signaling pathway | 3.67 | 0.13 | ID1, ID2, ID3, SMAD6, SMAD7, BMP4, BMP5, FMOD, RBX1 |
| FOXO signaling pathway | 2.33 | 0.09 | FBXO32, FOXO3, PLK2, PRKAB1, SGK1, HOMER3, GABARAPL1 |
| Thyroid cancer | 2.21 | 0.15 | GADD45B, GADD45G, TPM3, CDKN1A, CCND1 |
| Breast cancer | 2.01 | 0.08 | GADD45B, GADD45G, DLL4, CDKN1A, CCND1, NOTCH1 |
| Glioma | 2.00 | 0.10 | GADD45B, GADD45G, CCND1, CDKN1A, PDGFB |
| Endometrial cancer | 1.98 | 0.12 | GADD45B, GADD45G, CCND1, CDKN1A, AXIN2 |
| Small cell lung cancer | 1.89 | 0.09 | GADD45B, GADD45G, CCND1, CDKN1A, XIAP |
| Cardiac muscle contraction | 1.86 | 0.11 | MYH7B, MYH7, TNNC1, MYL3, MYH1B, ACTC1, TPM3 |
| Notch signaling pathway | 1.69 | 0.11 | HES4, NOTCH1, LFNG, JAG1, DLL4 |
| Calcium signaling pathway | 1.66 | 0.07 | ATP2A2, ATP2A3, ATP2B2, CAMK1D, CAMK4, GRIN2C |
| Nitrogen metabolism | 1.66 | 0.11 | HES4, NOTCH1, LFNG, JAG1, DLL4 |
| Apelin signaling pathway | 1.60 | 0.18 | PRKAB1, APLNR, MYLK3 |
| p53 signaling pathway | 1.54 | 0.09 | CDKN1A, CCND1, GADD45B, GADD45G, SESN1, AIFM2 |
| Ribosome biogenesis in eukaryotes | 1.51 | 0.09 | RPP38, RPP30, HEATR1, NOP56, NAT10, UTP4 |
| Pathways in cancer | 1.44 | 0.05 | GADD45B, GADD45G, XIAP, CDKN1A, CCND1, RBX1, ETS1 |
| Other types of O-glycan biosynthesis | 1.42 | 0.14 | LFNG, ST6GAL2, EOGT |
| Hippo signaling pathway | 1.41 | 0.07 | WWC1, CCND1, FRMD6 |
| Retinol metabolism | 1.40 | 0.11 | BCO1, ALDH1A2, CYP26A1, AOX1 |
| cAMP signaling pathway | 1.34 | 0.06 | EDNRA, RELA, SOX9, PDE3A |
| PI3K-Akt signaling pathway | 1.28 | 0.06 | ANGPT4, PDGFB, F2R, KITLG, KDR, FLT1 |
Figure 6ROS induces myotube atrophy. (A) Morphological changes in CPM treated with DMNQ for 12 h and 24 h. (B) Fluorescence map for ROS level in CPM treated with DMNQ for 12 h. (C) Statistics of the fluorescence quantity for ROS content in CPM treated with DMNQ for 12 h. (D) Analysis of CAT activity in CPM under DMNQ treatment for 12 h. (E) Analysis of MDA content in CPM under DMNQ treatment for 12 h. (F) Analysis of total antioxidant capacity in CPM under DMNQ treatment for 12 h. (G) Expression of genes related to muscle fiber types after treatment with DMNQ for 12 h. (H) Grayscale graph of the protein expression level after treatment with DMNQ for 12 h. (I) Statistical graph of the protein expression level after treatment with DMNQ for 12 h. (J) Expression of genes related to muscle atrophy and potential anti-oxidation after treatment with DMNQ for 12 h. (K) Expression of genes related to cell cycle and apoptosis after treatment with DMNQ for 12 h. Data are presented as mean ± SEM (n = 6 biologically independent samples). * p < 0.05; ** p < 0.01; *** p < 0.001 (Student’s t-test).
Figure 7Schematic diagram of disuse muscle atrophy model.